We have just released a list of 10 companies that are performing well despite the market decline. In this article, we will examine how Bausch Health Companies Inc. (NYSE:BHC) compares to these other standout firms. On Thursday, negative feelings continued in the stock market as investors chose to sell off their shares.
Bausch Health reported strong Q4 results with a 6.2% Y/Y revenue increase and positive net income, driving a 10% stock rally. Key growth drivers include Salix, Xifaxan, and Solta, with a focus on long-term growth and debt management, peaking in 2028. Positive catalysts include FDA litigation outcomes and strategic decisions around Bausch & Lomb, enhancing shareholder value and future revenue potential.
BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.
Bausch Health Companies Inc. (NYSE:BHC ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Conference Call Participants Les Sulewski - Truist Securities Doug Miehm - RBC Capital Michael Freeman - Raymond James Michael Nedelcovych - TD Cowen Glen Santangelo - Jefferies Operator Greetings. Welcome to the Bausch Health Fourth Quarter 2024 Earnings Call.
Bausch Health (BHC) came out with quarterly earnings of $1.21 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.15 per share a year ago.
Seventh consecutive quarter of year-over-year growth in both Revenue and Adjusted EBITDA (non-GAAP)1, delivering results at the high-end and/or exceeding 2024 guidance Fourth Quarter Consolidated Revenues of $2.56 billion, up 6% on a Reported basis and up 9% on an Organic (non-GAAP)1 basis over the prior year period Full-Year Consolidated Revenues of $9.63 billion, up 10% on a Reported basis and 8% on an Organic (non-GAAP)1 basis, with growth in all segments GAAP Net Income Attributable to Bausch Health Companies Inc. of $93 million for the quarter and GAAP Net Loss of $46 million for the year Consolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $935 million for the quarter, up 8%, and $3.31 billion for the year, up 10% LAVAL, QC / ACCESS Newswire / February 19, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" the "Company," "we" or "our") today announced its fourth quarter and full-year 2024 financial results and other key updates for the quarter. "2024 was a year of delivering on our commitments, where we achieved the high-end of our revenue guidance range, and exceeded our adjusted EBITDA excluding Bausch + Lomb, and adjusted operating cash flow guidance expectations.
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth Technological Advancements in Microcurrent and Radiofrequency Devices Propel Market Growth
Bausch Health to Provide Scholarships to 10 Students Living with GI Diseases LAVAL, QC / ACCESS Newswire / February 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the opening of the 2025 Salix Gastrointestinal Health Scholars Program application period. The program will award 10 exceptional students living with GI disease a scholarship of up to $10,000 as they work to pursue their higher education goals.
LAVAL, QC / ACCESS Newswire / February 6, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following update on a potential sale of its subsidiary, Bausch + Lomb Corporation (NYSE:BLCO)(TSX:BLCO), which was disclosed in December 2024 following a regulatory request: "In the second half of 2024, Bausch Health engaged with its financial advisors to work on various liability management alternatives. At the same time, Bausch + Lomb was approached by a private equity firm with an indication of interest for a potential sale of Bausch + Lomb at a compelling valuation.